JavaScript is disabled in your browser. Please enable JavaScript to view this website.

TNNI3

GeneName

TNNI3

Summary

TNNI3, also known as cardiac troponin I, is a 24 kDa protein that is a key component of the cardiac troponin complex, which is located within the cardiac myofibril and sarcomere. It plays a critical role in regulating cardiac muscle contraction by inhibiting the interaction between actin and myosin in the presence of calcium ions. TNNI3 is involved in various processes such as heart development, intracellular calcium ion homeostasis, and muscle filament sliding, and it binds to troponin C and troponin T, contributing to the overall function of the troponin complex in cardiac and skeletal muscle tissues.

Importance

TNNI3 is relevant to: - Heart disease research, particularly in the context of cardiac dysfunction and heart failure due to its role in muscle contraction regulation - Biomarker development for myocardial injury, as elevated levels of cardiac troponin I are indicative of cardiac events - Studies on calcium signalling and its effects on muscle contraction, which are crucial for understanding arrhythmias and other cardiac conditions - Investigations into muscle development and regeneration, which have implications for therapies in muscular dystrophies and other muscle-related disorders

Top Products

For researchers investigating TNNI3, we recommend two excellent primary antibodies. The first is the well-cited polyclonal antibody, Anti-Cardiac Troponin I antibody (ab47003), which has garnered 168 citations, reflecting its strong reputation in the field. This antibody is highly effective for Western blotting (WB), immunohistochemistry (IHC), and immunocytochemistry (ICC). Additionally, we offer the recombinant antibody, Anti-Cardiac Troponin I antibody [EP1106Y] (ab52862). This product is validated for a broader range of applications, including WB, IHC, flow cytometry (FC), and immunoprecipitation (IP). With 21 citations, it is gaining traction among researchers who appreciate the consistency and reliability that recombinant antibodies provide. Together, these antibodies represent a robust toolkit for studying TNNI3. The Human Cardiac Troponin I ELISA Kit (ab229404) is an excellent option for researchers looking to measure TNNI3 levels in their samples.

Abcam Product Citation Summary

The research involving TNNI3 primarily focuses on cardiac contexts, including studies on myocarditis, myocardial infarction, and cardiac myocyte responses to various treatments. The use of different applications such as Western blot and immunohistochemistry highlights the importance of TNNI3 in understanding cardiac function and pathology.

Abcam Product Citation Table

ab200016
Human
Treg cells in myocarditis
29977885
ab47003
Mouse
IHC
Hearts following myocardial infarction
32355240
ab52862
Human
WB
Cardiac myocytes and remifentanil preconditioning
32584786
ab52862
Human
ICC-IF
Cardiomyocytes derived from T07
24465630
ab52862
Human
ICC-IF
Cardiomyocytes derived from TiPSC-CMs
24465630
ab56357
Mouse
IHC
Heart tissue in cardiomyocyte study
29403069
ab56357
Mouse
IHC
Heart tissue and Sema3a expression
29403069
ab56357
Mouse
IHC-IF
Heart sections in Sema3a-CreERT2 knock-in study
29403069
ab56357
Mouse
IHC
Heart tissue and Sema3a expression map
29403069
ab56357
Mouse
IF
Myocardium in aortic valve disease study
36277751

Function

Troponin I is the inhibitory subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity.

Involvement in disease

Cardiomyopathy, familial hypertrophic, 7

CMH7

A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death.

None

The disease is caused by variants affecting the gene represented in this entry.

Cardiomyopathy, familial restrictive 1

RCM1

A heart disorder characterized by impaired filling of the ventricles with reduced diastolic volume, in the presence of normal or near normal wall thickness and systolic function.

None

The disease is caused by variants affecting the gene represented in this entry.

Cardiomyopathy, dilated, 2A

CMD2A

A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.

None

The disease is caused by variants affecting the gene represented in this entry.

Cardiomyopathy, dilated, 1FF

CMD1FF

A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.

None

The disease is caused by variants affecting the gene represented in this entry.

Post-translational modifications

Phosphorylated at Ser-42 and Ser-44 by PRKCE; phosphorylation increases myocardium contractile dysfunction (By similarity). Phosphorylated at Ser-23 and Ser-24 by PRKD1; phosphorylation reduces myofilament calcium sensitivity. Phosphorylated preferentially at Thr-31. Phosphorylation by STK4/MST1 alters its binding affinity to TNNC1 (cardiac Tn-C) and TNNT2 (cardiac Tn-T).

Sequence Similarities

Belongs to the troponin I family.

Alternative names

TNNC1, TNNI3, Cardiac troponin I

swissprot:P19429 omim:191044 entrezGene:7137